Meeting
2015 ASCO Annual Meeting
Baseline carcinoembryonic antigen (CEA) serum levels to predict bevacizumab-based treatment response in patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving 1st-line therapy with FOLFIRI plus cetuximab or bevacizumab (AIO KRK0306, FIRE3 trial).
Authors
Marlies Michl
Department of Hematology and Medical Oncology and Comprehensive Cancer Center, University Hospital Grosshadern, LMU Munich, Munich, Germany
Marlies Michl , Ludwig Fischer von Weikersthal , Thomas Decker , Alexander Kiani , Ursula Vehling-Kaiser , Salah-Eddin Al-Batran , Tobias Heintges , Christian Lerchenmueller , Christoph Kahl , Gernot Seipelt , Frank Kullmann , Martina Stauch , Werner Scheithauer , Joerg Hielscher , Michael Scholz , Dominik Paul Modest , Sebastian Stintzing , Thomas Kirchner , Andreas Jung , Volker Heinemann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3581)
DOI
10.1200/jco.2015.33.15_suppl.3581
Abstract #
3581
Poster Bd #
74
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
AIO KRK0306, FIRE3 trial: CEA and CA19-9 influence outcome of patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving first-line therapy with FOLFIRI plus cetuximab or bevacizumab.
First Author: Marlies Michl
Poster
2015 Gastrointestinal Cancers Symposium
Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.
First Author: Sebastian Stintzing
Poster
2015 Gastrointestinal Cancers Symposium
GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectal cancer (mCRC).
First Author: John A. Bridgewater
Poster
2023 ASCO Annual Meeting
RAS testing of circulating cell-free DNA (cfDNA) from tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients: Preliminary data from the Liquid Biopsy Monoclonal Antibodies in mCRC (LIBImAb) study.
First Author: Anna Maria Rachiglio